A Deep Dive into Digital Biomarkers for Cognitive Impairment with Liam Kaufman, co-founder at Winterlight Labs

Changes in healthcare don't happen quickly, but the horizon is full of new opportunities to embrace. In this episode, Liam Kaufman, co-founder at Winterlight Labs, explains how his company utilizes digital biomarkers, analyzing speech and machine learning, to quantify cognitive impairment and mental health. Liam highlights they are adding to the healthcare ecosystem by providing efficient and objective measures for pharmaceutical companies to gauge treatment effectiveness, and shares the significant impact of voice biomarkers, detailing how they enable quicker and more objective assessments compared to traditional methods. He emphasizes the role of technology in remote patient testing, particularly in the context of Alzheimer's disease, and underlines the potential of large language models like ChatGPT to automate administrative tasks in healthcare. Liam also reflects on the current landscape of digital health, expressing optimism amid challenges and foreseeing positive changes in the industry. Tune in and learn about the cutting-edge work at Winterlight Labs and the evolving landscape of digital health! Resources:  Connect and follow Liam Kaufman on LinkedIn here. Follow WinterLight Labs on LinkedIn. Learn more about WinterLight Labs on their website. Listen to Liam’s previous interview here.